Charts

InvestorPlace - Stock Market News, Stock Advice & Trading Tips OCGN stock results show that Ocugen beat analyst estimates for earnings per share the fourth quarter of 2023. The post OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Law Offices of Howard G. Smith announces an investigation on behalf of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) investors concerning the Company’s possible violations of federal securities laws.

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024. Details of the fires

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Ocugen investors under the federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned statistical analysis of the pivotal OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) resulting from allegations that Ocugen may have issued materially misleading business information to the investing public.

Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent. The post Why Is Auddia (AUUD) Stock Up 192% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 7.7% to $1.97 during Monday’s session after the company announced U.S. FDA ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen is returning to its eye treatment roots after a brief life as a Covid-19 vaccine meme stock in 2021 delivered OCGN stock no results. The post Why Is Ocugen (OCGN) Stock Up 7% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their ...

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP).

Ocugen, Inc. (NASDAQ:OCGN) shares are trading higher Friday after the company announced it has received approval to proceed dosing with ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With Ocugen receiving a green light to move ahead with a key retinal therapeutic, OCGN stock jumped on the positive implications. The post OCGN Stock Alert: Why Is Ocugen Up 20% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 14% to $1.58 during Wednesday’s session. The company yesterday provided an ...

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE: SIG) rose ...

Q4 2023 Ocugen Inc Earnings Call

OCGN earnings call for the period ending March 31, 2024.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After an impressive rally to date, investors appear to be in selling mode with OCGN stock on the news it will need to restate its financials. The post OCGN Stock Falls Ocugen Must Restate Its Financials appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Conference Call and Webcast Today at 8:30 a.m. ETReceived alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt dise

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter. • ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU410ST clinical trial recently convened and approved to

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024. Ocugen will issue a pre-market earnings announcement on the same day. A

U.S. stock futures were higher this morning, with the Dow futures gaining by over 100 points on Monday. Shares of Oxford Industries, ...

Ocugen Inc (NASDAQ:OCGN) shares traded lower by 6.3% to $1.72 during Tuesday’s session before flattening out, pulling back after ...

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors are wondering if the stock market is closed on Good Friday 2024 as they prepare for the upcoming Easter weekend. The post Is the Stock Market Closed on Good Friday 2024? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million. The post Why Is Landos Biopharma (LABP) Stock Up 168% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen stock is heading higher on Friday as investors in OCGN shares react to a dismissed class action lawsuit against the company. The post Why Is Ocugen (OCGN) Stock Up 20% Today? appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Discover three stocks under $5 from SaaS transformation to biotech advancements, that showcase immense potential for market outperformance. The post 3 Stocks Under $5 Ready to Outpace the Market appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth ...

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. (NYSE: WS) ...

Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported ...

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported ...

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday. Shares of Guess?, Inc. (NYSE: GES) rose ...

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. “This appointment recognizes her invaluab

MALVERN, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD). GA

Could these biotech companies still win in the vaccine market and beyond?

MALVERN, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will be a panelist at the Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont Scottsdale Princess Hotel in Scottsdale, AZ. “I look forward to joining my peers in

MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website. The showcase replay includes more detail on the Phase 3 study design for OCU400, as well as market potential

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These once-popular meme stocks are now in free-fall, highlighting the urgent need to offload them from your portfolios. The post Meme Stock Meltdowns: 3 Names to Sell Before They Crash appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter ...

MALVERN, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the Abu Dhabi Family Office (ADFO) Summit being held February 29—March 1, 2024 at the Saadiyat Rotana Resort and Villas in Abu Dhabi, United Arab Emirate

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease is an orphan blindness disease that affects approximat

MALVERN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 26-27, 2024, at the Marriott Marquis in New York City. Members of Ocugen’s leadership team will con

Gainers Inspire Veterinary (NASDAQ:IVP) stock increased by 47.8% to $0.2 during Wednesday's pre-market session. The market value of ...

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. Fluor posted adjusted ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen stock is rising higher on Tuesday as OCGN fans prepare for a Clinical Showcase tomorrow that could be a positive catalyst for shares. The post Dear OCGN Stock Fans, Mark Your Calendars for Feb. 21 appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

Shares of Discover Financial Services (NYSE: DFS) shares rose sharply in today’s pre-market trading. Capital One Financial ...

Gainers Trxade Health (NASDAQ:MEDS) shares rose 207.2% to $14.1 during Tuesday's pre-market session. The company's market cap stands at ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Tuesday morning as we start the day with a breakdown of all the latest stock market news! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

National Philanthropic Trust Welcomes New Board Members Jeffrey Armbrister, Lindy Benton-Moreno, and Connie Collingsworth